欧洲液态切片市场（按最终用户和国家/地区划分）-分析和预测（2024-2033 年）

预计 2024 年欧洲液态切片市场价值将达到 12.4 亿美元。

预计到 2033 年，市场规模将达到 55.8 亿美元，在 2024-2033 年预测期内，复合年增长率将达到 18.18%。在欧洲，液态切片是一种新型非侵入性诊断技术，正在彻底改变癌症的检测和监测。该方法有可能早期发现癌症復发并评估治疗的效果，并能够以微创的方式进行即时监测。癌症发生率不断上升、研究论文和临床试验数量不断增加是推动液态切片市场成长的一些因素。这些因素导致对液态切片测试和产品的需求量很大。随着人们对微创癌症检测方法的日益偏好，更具创新性和效率的检测方法正在更快地开发。

政府旨在改善癌症检测和治疗管理的措施也大大促进了市场的成长。液态切片产品可透过各种通路广泛获得，包括线上平台和零售店，确保更广泛的覆盖范围和改善欧洲消费者的获取。这些综合因素正在推动欧洲液态切片市场的发展，并支持向更有效率、更容易获得的癌症检测解决方案的转变。

随着非侵入性诊断技术彻底改变了癌症监测和检测，欧洲液态切片市场正在大幅扩张。液态切片可以检查血液样本中的循环肿瘤 DNA (ctDNA)、RNA 和外泌体，是传统切片检查技术的有力替代方法。液态切片因其能够提供即时监测、识别早期癌症復发和评估治疗效果，在肿瘤学领域越来越受欢迎。

欧洲癌症发生率的不断上升、对微创诊断技术的需求不断增长以及研究和临床试验的不断改进是推动该市场成长的一些因素。随着液态切片技术的进步，它将支持个人化医疗策略，并能够在更易于治疗的阶段更早发现癌症。此外，液态切片的应用范围正在扩大到肿瘤学以外的领域，包括循环系统、神经科和感染疾病。

旨在鼓励采用最尖端科技和加强癌症诊断的政府计划和监管支持也在推动欧洲市场的发展。学术界、医疗保健提供者和产业领袖之间的伙伴关係以及不断增加的研究资金进一步推动了市场的扩张。随着零售店和网路平台等通路的扩大，液态切片产品越来越广泛地提供给欧洲各地的患者和医疗保健提供者。

本报告研究了欧洲液态切片市场，提供了市场概况、最终用户和国家趋势，以及参与市场的公司概况。

目录

执行摘要

第一章 市场

• 市场趋势
• 供应链分析：欧洲液态切片市场
• 法律规范
• COVID-19 对欧洲液态切片市场的影响
• 最近推出的产品/服务
• 赎回情况
• 资金筹措方案
• 产品映射分析
• 市场总规模及渗透率
• 欧洲液态切片市场：相关利益者分析 (N=30)
• 政府关于液态切片的倡议
• 市场动态概览

第二章 区域

• 欧洲

第三章 市场竞争基准化分析与公司概况

• 公司简介
  • Dxcover Limited
  • F. Hoffmann-La Roche Ltd.
  • GENinCode PLC (Abcodia Ltd.)
  • QIAGEN NV

第四章调查方法

Introduction to Europe Liquid Biopsy Market

The Europe liquid biopsy market, valued at $1.24 billion in 2024, is expected to reach $5.58 billion by 2033, exhibiting a robust CAGR of 18.18% during the forecast period 2024-2033. In Europe, liquid biopsy is a new non-invasive diagnostic technique that is transforming cancer detection and surveillance. This method has the potential to early detect cancer recurrence or evaluate treatment responses, and it provides real-time monitoring with minimal invasiveness. The growing prevalence of cancer, rising research publications, and clinical trials are some of the factors driving the growth of the liquid biopsy market. These factors are creating higher demand for liquid biopsy tests and products. More innovative and efficient tests have been developed more quickly as a result of the growing preference for minimally invasive cancer detection methods.

The market's growth has also been greatly aided by government initiatives aimed at improving cancer detection and treatment management. Because liquid biopsy products are widely accessible through a variety of distribution channels, such as online platforms and retail stores, is enhancing accessibility and ensuring a broader reach to consumers across Europe. These combined factors are helping the liquid biopsy market in Europe gain significant traction, supporting the transition to more efficient and accessible cancer detection solutions.

Market Introduction

The market for liquid biopsies in Europe is expanding significantly as a non-invasive diagnostic technique that is revolutionizing cancer monitoring and detection. A potent substitute for conventional biopsy techniques, liquid biopsy examines blood samples for circulating tumor DNA (ctDNA), RNA, and exosomes. Its use in oncology is being fueled by its capacity to offer real-time monitoring, identify early cancer recurrence, and evaluate the effectiveness of treatment.

The growing incidence of cancer throughout Europe, the growing demand for minimally invasive diagnostic techniques, and continuous improvements in research and clinical trials are some of the factors driving this market's growth. As liquid biopsy technology advances, it supports personalized medicine strategies and allows early cancer detection at more treatable stages. Furthermore, the expansion of liquid biopsy applications extends beyond oncology, including uses in cardiology, neurology, and infectious diseases.

Government programs and regulatory assistance aimed at advancing the adoption of cutting-edge technologies and enhancing cancer diagnostics are also driving the European market. Further propelling market expansion are partnerships between academia, healthcare providers, and industry leaders, as well as increased research funding. The expansion of distribution channels, such as retail stores and internet platforms, is making liquid biopsy products more widely available to patients and healthcare providers throughout Europe.

Market Segmentation:

Segmentation 1: by End User

• Academic and Research Institutions
• Clinical Laboratories
• Pharmaceutical and Biotechnology
• Companies
• Other End Users

Segmentation 2: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe liquid biopsy market has been segmented based on various categories, such as end user and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe liquid biopsy market is highly fragmented, with many smaller and private companies constantly entering the market. Key players in the liquid biopsy market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Dxcover Limited
• F. Hoffmann-La Roche Ltd.
• GENinCode Plc (Abcodia Ltd.)
• QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Market

• 1.1 Market Trends
  • 1.1.1 Increasing Product Launches in the Market
  • 1.1.2 Growing Funding by the Key Players in the Market
• 1.2 Supply Chain Analysis: Europe Liquid Biopsy Market
• 1.3 Regulatory Framework
  • 1.3.1 Regulatory Framework in the European Union (EU)
  • 1.3.2 Regulation in Other Countries
• 1.4 COVID-19 Impact on Europe Liquid Biopsy Market
• 1.5 Recently Launched Product/Services
• 1.6 Reimbursement Scenario
• 1.7 Financing Scenario
  • 1.7.1 Key Players Patent Portfolio
  • 1.7.2 Key Players Stratification as per Raised Financing Value
  • 1.7.3 Key Players Financing Analysis (by Company)
• 1.8 Product Mapping Analysis
  • 1.8.1 By Technology
  • 1.8.2 By Sample
  • 1.8.3 By Circulating Biomarker
  • 1.8.4 By Clinical Application
• 1.9 Total Addressable Market and Penetration
• 1.1 Europe Liquid Biopsy Market: Stakeholder Analysis (N=30)
  • 1.10.1 Physicians' Perception
  • 1.10.2 Payer's Perception
  • 1.10.3 Investors' Perception
• 1.11 Liquid Biopsy Government Initiatives
• 1.12 Market Dynamics Overview
  • 1.12.1 Market Drivers
    • 1.12.1.1 Rising Burden of Cancer
    • 1.12.1.2 Growing Research Publications and Clinical Trials in Liquid Biopsy
    • 1.12.1.3 Growing Adoption and Demand of Minimally Invasive Cancer Detection Methods
  • 1.12.2 Market Restraints
    • 1.12.2.1 Technical Limitations in Liquid Biopsy
    • 1.12.2.2 Uncertain Reimbursement and Recommendations for Liquid Biopsy Tests
  • 1.12.3 Market Opportunities
    • 1.12.3.1 Integration of AI in Liquid Biopsy
    • 1.12.3.2 Use of Liquid Biopsy for Precision Medicine in Oncology

2 Regions

• 2.1 Europe
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Test Volume
  • 2.1.5 Market Size and Forecast
    • 2.1.5.1 By End User
  • 2.1.6 Germany
    • 2.1.6.1 Test Volume
    • 2.1.6.2 Market Size and Forecast
      • 2.1.6.2.1 By End User
  • 2.1.7 U.K.
    • 2.1.7.1 Test Volume
    • 2.1.7.2 Market Size and Forecast
      • 2.1.7.2.1 End User
  • 2.1.8 France
    • 2.1.8.1 Test Volume
    • 2.1.8.2 Market Size and Forecast
      • 2.1.8.2.1 By End User
  • 2.1.9 Italy
    • 2.1.9.1 Test Volume
    • 2.1.9.2 Market Size and Forecast
      • 2.1.9.2.1 By End User
  • 2.1.10 Spain
    • 2.1.10.1 Test Volume
    • 2.1.10.2 Market Size and Forecast
      • 2.1.10.2.1 By End User
  • 2.1.11 Rest-of-Europe
    • 2.1.11.1 Test Volume
    • 2.1.11.2 Market Size and Forecast
      • 2.1.11.2.1 By End User

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Dxcover Limited
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Key Personnel
    • 3.1.1.5 Analyst View
  • 3.1.2 F. Hoffmann-La Roche Ltd.
    • 3.1.2.1 Overview
    • 3.1.2.2 Top Products
    • 3.1.2.3 Top Competitors
    • 3.1.2.4 Key Personnel
    • 3.1.2.5 Analyst View
  • 3.1.3 GENinCode PLC (Abcodia Ltd.)
    • 3.1.3.1 Overview
    • 3.1.3.2 Top Products
    • 3.1.3.3 Top Competitors
    • 3.1.3.4 Key Personnel
    • 3.1.3.5 Analyst View
  • 3.1.4 QIAGEN N.V.
    • 3.1.4.1 Overview
    • 3.1.4.2 Top Products
    • 3.1.4.3 Top Competitors
    • 3.1.4.4 Key Personnel
    • 3.1.4.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Liquid Biopsy Market, $Million, 2024, 2028, and 2033
• Figure 2: Liquid Biopsy Market (by Region), $Million, 2023, 2027, and 2033
• Figure 3: Key Events to Keep Track of in the Liquid Biopsy Market
• Figure 4: Impact of COVID-19 on Liquid Biopsy Market
• Figure 5: Patent Published (by Country), January 2021-May 2024
• Figure 6: Number of Liquid Biopsy Patents (by Year), January 2021-May 2024
• Figure 7: Financing Analysis (by Latest Deal Amount), $Million, FY2023-2024
• Figure 8: Europe Liquid Biopsy Market Scenario, 2023
• Figure 9: Frequently Used Technology in Liquid Biopsy
• Figure 10: Most Important Factors for Adoption of NGS-Based Liquid Biopsy
• Figure 11: Treatment Guidelines for Treatment of Cancer Patients
• Figure 12: Major Challenges Faced While Performing Liquid Biopsy
• Figure 13: Average Cost of Technologies for the Europe Liquid Biopsy Market (N=30 )
• Figure 14: Cost Difference Across Different End Users for the Europe Liquid Biopsy Market
• Figure 15: Key Factors for Determining Reimbursement Possibility for the Europe Liquid Biopsy Market
• Figure 16: Estimated Global Cancer Incidence in 2020 and 2040
• Figure 17: Estimated New Cancer Cases (2022-2045): Both Sexes, Ages 0-85
• Figure 18: Upsurge in Research Publications in Liquid Biopsy, 2015-2023
• Figure 19: Comparison of Liquid Biopsy vs. Tissue Biopsy
• Figure 20: Europe Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 21: Europe Liquid Biopsy Market, $Million, 2023-2033
• Figure 22: Germany Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 23: Germany Liquid Biopsy Market, $Million, 2023-2033
• Figure 24: U.K. Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 25: U.K. Liquid Biopsy Market, $Million, 2023-2033
• Figure 26: France Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 27: France Liquid Biopsy Market, $Million, 2023-2033
• Figure 28: Italy Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 29: Italy Liquid Biopsy Market, $Million, 2023-2033
• Figure 30: Spain Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 31: Spain Liquid Biopsy Market, $Million, 2023-2033
• Figure 32: Rest-of-Europe Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 33: Data Triangulation
• Figure 34: Top-Down and Bottom-Up Approach
• Figure 35: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Liquid Biopsy Market, Market Opportunities
• Table 3: Product Launches, January 2021-April 2024
• Table 4: Some of the Strategic Funding, January 2022-April 2024
• Table 5: Launched Liquid Biopsy Tests from Players in the Liquid Biopsy Market
• Table 6: Reimbursement Scenario for Key Players' Offerings in the Liquid Biopsy Market
• Table 7: Europe Liquid Biopsy Market: Key Players Patent Portfolio
• Table 8: Liquid Biopsy Product Mapping Analysis (by Technology)
• Table 9: Liquid Biopsy Product Mapping Analysis (by Sample)
• Table 10: Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker)
• Table 11: Liquid Biopsy Product Mapping Analysis (by Clinical Application)
• Table 12: Government Initiatives for Liquid Biopsies
• Table 13: Impact Analysis of Market Navigating Factors, 2023-2033
• Table 14: Liquid Biopsy Market (by Region), $Million, 2023-2033
• Table 15: Europe Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 16: Germany Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 17: U.K. Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 18: France Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 19: Italy Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 20: Spain Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 21: Rest-of-Europe Liquid Biopsy Market, $Million, 2023-2033
• Table 22: Rest-of-Europe Liquid Biopsy Market (by End User), $Million, 2023-2033